注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Verrica Pharmaceuticals Inc是一家皮肤科治疗公司。该公司专注于开发和商业化治疗皮肤病的新疗法。其主要候选产品VP-102是斑蝥素局部溶液的药物-器械组合,斑蝥素是一种广泛认可的用于治疗局部皮肤病的天然来源的药物,该产品通过一次性精密涂药器给药。该公司正在开发 VP-102,用于治疗传染性软疣(软疣),这是一种高度传染性且主要是小儿病毒性皮肤病、外生殖器疣和普通疣。该公司还打算开发第二个基于斑蝥素的候选产品VP-103,用于治疗足底疣。它还打算开发其第三个候选产品LTX-315,用于治疗皮肤肿瘤适应症,包括非转移性黑色素瘤和非转移性默克尔细胞癌。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Sean Stalfort | 51 | 2015 | Director |
Mark Lebwohl | - | - | Member of Scientific Advisory Board |
Elaine Siegfried | - | - | Member of Scientific Advisory Board |
Craig Ballaron | 60 | 2019 | Independent Director |
Ted White | 56 | 2017 | President, CEO & Director |
Janice Pelletier | - | - | Member of Scientific Advisory Board |
Mark A. Prygocki | 54 | 2018 | Independent Director |
Paul B. Manning | 65 | 2015 | Chairman of the Board |
Robert Greenberg | - | - | Member of Scientific Advisory Board |
Steven Cohen | - | - | Member of Scientific Advisory Board |
Anthony Mancini | - | - | Member of Scientific Advisory Board |
Diem Nguyen | 49 | 2020 | Independent Director |
Lawrence F. Eichenfield | 64 | 2020 | Independent Director |
Adelaide Hebert | - | - | Member of Scientific Advisory Board |
Richard J. Antaya | - | - | Member of Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核